Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Zepbound is most effective when combined with a balanced diet and regular exercise. Eating plenty of filling and nutrient-dense foods can help you work toward your weight loss goals. Zepbound ...

If you’re living with overweight or obesity and are interested in exploring Zepbound as a treatment option, consulting a healthcare professional for a comprehensive evaluation is crucial.

A microsimulation model published in JAMA Health Forum projected that Medicare expenditures would increase by $47.7 billion over 10 years if drugs such as Wegovy and Zepbound were covered under ...

With other races on the horizon, she decided to go back on tirzepatide, the active ingredient in popular diabetes and weight-loss drugs Mounjaro and Zepbound. She had used it before to take off ...

The Eli Lilly metabolic medicines Mounjaro and Zepbound were also in short supply. Persisting shortages left the door open for compounders to step up to meet the market demand with their versions ...

So did Eli Lilly, which makes the weight-loss drug Zepbound and Mounjaro, a similar drug tailored to diabetes patients. Together, the two companies hired more than 10 lobbying firms, including top ...